Return to search results.
Complete title: An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma
|Research Study Number||20131088|
|Principal Investigator||Marc Chamberlain, MD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Astrocytomas; Brain Cancer; Glioblastoma Multiforme; Glioma; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.